PD-0325901 (Not yet branded)
Other Medications
Description
PD-0325901 is a potent, selective MEK inhibitor that targets the mitogen-activated protein kinase (MAPK) signaling pathway in colorectal cancer. This compound has been evaluated specifically in combination therapies for KRAS-mutant colorectal cancers, where aberrant MEK signaling drives tumor growth. It represents a targeted approach to block downstream effects of KRAS mutations, which occur in approximately 40-50% of colorectal cancer patients and confer resistance to EGFR-targeted therapies.
Mechanism of Action
PD-0325901 works by selectively inhibiting MEK1 and MEK2, which are critical kinases in the RAS/RAF/MEK/ERK signaling cascade. By blocking MEK activity, the drug prevents phosphorylation and activation of ERK, thereby disrupting cellular proliferation, survival signals, and tumor growth in KRAS-mutant cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.